Research Funded To Date

BIOMARKERS FOR MONITORING TREATMENT RESPONSE AND CHANGES IN THE MOLECULAR MAKEUP OF GLIOBLASTOMA ARE LIMITED. PROJECT WILL USE GENOMIC ANALYSES OF RESECTED TUMORS AND PERIPHERAL PLASMA SAMPLES TO ASSESS THE FEASIBILITY OF CIRCULATING DNA-BASED DIAGNOSTICS IN PATIENTS WITH GLIOBLASTOMA.

PI: Muhammed Murtaza, Ph.D.
Co-Director, Center for Noninvasive Diagnostics
Translational Genomics Research Institute (TGen)

Award: $3,000,000 over four years


PD-1 BLOCKADE TO OVERCOME INHERENT TUMOR IMMUNOSUPPRESSION WILL BE COMBINED WITH AN INNOVATIVE, PATIENT-SPECIFIC NEOANTIGEN VACCINE TO DRIVE TUMOR IMMUNOGENICITY IN A PHASE 2 CLINICAL.

PI: David A. Reardon, M.D.
Clinical Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute

Award: $1,500,000 over three years


PROJECT WILL STUDY THE ABILITY TO IMAGE A KEY REGULATORY SWITCH IN GLIOBLASTOMA METABOLISM BY THE USE OF PET IMAGING. A NEW PET TRACER TARGETING PKM2 WILL BE USED TO IMAGE THE EARLIEST CHANGES IN RESPONSE TO TREATMENT IN ORDER TO HELP IMPROVE GBM PATIENT MANAGEMENT.

PI: Sanjiv Sam Gambhir M.D., Ph.D.
Chair, Department of Radiology
Director, Molecular Imaging Program at Stanford
Director, Canary Center at Stanford for Cancer Early Detection
Stanford University School of Medicine

Award: $1,461,240 over three years


FUNDING WILL ACCELERATE THE PHASE 0 NEURO-ONCOLOGY CLINICAL TRIAL PROGRAM BY SUPPORTING ESSENTIAL INFRASTRUCTURE, INCLUDING BASIC AND CLINICAL SCIENCE INVESTIGATORS, RESEARCH NURSES, BIOSTATISTICIANS AND A PROGRAM MANAGER. THIS PHASE 0 PROGRAM IS THE FIRST SUCH PROGRAMMATIC EFFORT FOR GLIOBLASTOMA PATIENTS WORLDWIDE.

PI: Nader Sanai, M.D., FAANS, FACS
Director, Division of Neurosurgical Oncology
Director, Barrow Brain Tumor Research Center
Barrow Neurological Institute

Award: $250,000 over two years


SUPPORT A NEW PHASE 0/11 CLINICAL TRIAL TESTING A FIRST-IN-CLASS TARGETED INHIBITOR FOR A MOLECULAR SUBSET OF RECURRENT GLIOBLASTOMA PATIENTS WITH THE HIGHEST LIKELIHOOD OF DRUG EFFECT.

PI: Nader Sanai, M.D., FAANS, FACS
Director, Division of Neurosurgical Oncology
Director, Barrow Brain Tumor Research Center
Barrow Neurological Institute

Award: $300,860 over two years


PHASE 1 CLINICAL TRIAL EVALUATING AN AUTOLOGOUS BRAIN TUMOR STEM CELL RNA BASED DENDRITIC CELL VACCINE FOR THE TREATMENT OF MALIGNANT GLIOMA. PATIENTS WILL RECEIVE A PERSONALIZED DENDRITIC CELL VACCINE TO ELICIT AN IMMUNE RESPONSE AGAINST THEIR TUMORS IN CONJUNCTION WITH A PROGRAMMED CELL DEATH 1 (PD-1) INHIBITOR.

PIs: Charles S. Cobbs, M.D.
Director, Ivy Center for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute

Parvinder Hothi, Ph.D.
Ivy Center for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute

Award: $1,050,000 over three years


UTILIZING A SMALL MOLECULE AND NANOPARTICLE FORMULATED STAT3 INHIBITOR TO STOP THE PROCESS OF TUMORIGENESIS AND TUMOR-MEDIATED IMMUNE SUPPRESSION IN A PHASE I/II CLINICAL TRIAL WITH UNIQUE CORRELATIVE BIOMARKERS OF POTENTIAL CLINICAL RESPONSE.

PIs: Amy Heimberger, M.D.
Professor, Neurosurgery
MD Anderson Cancer Center

Waldemar Priebe, M.Sc., Ph.D.
Professor, Experimental Therapeutics Department
MD Anderson Cancer Center

Charles A. Conrad, M.D.
Professor, Neuro-Oncology
MD Anderson Cancer Center

Award: $2,000,000 over four years


NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM AT TGEN DESIGNED TO GIVE HIGH SCHOOL AND UNDERGRADUATE STUDENTS INTENSIVE, HANDS-ON RESEARCH EXPERIENCE WORKING ALONGSIDE A MENTOR-SCIENTIST TO LEARN ABOUT TRANSLATIONAL RESEARCH WHILE INVESTIGATING QUESTIONS WITHIN THE NEUROLOGICAL SCIENCES.

PI: Brandy Wells
Director, Public Affairs and Education
Translational Genomics Research Institute (TGen)

Award:  $91,824